CytoMed Therapeutics Limited GDTC
0.96
0.05
5.49%
as of 25 Sep
- Market cap
- $10.8M
- P/E
- 0.0×
Follow GDTC
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | |
|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | — | — | — |
P/S ratio |
0.00 | 0.00 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | — | — | — | — |
P/Operating CF |
(1,265.17) | (4,651.77) | — | — | — | — |
P/B ratio |
682.30 | 1,394.17 | — | — | — | — |
Price to Tangible BV |
694.96 | 1,408.66 | — | — | — | — |
EV/Sales |
0.00 | 0.00 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(521.73) | (1,328.79) | — | — | — | — |
EV/FCF |
(395.63) | (1,091.57) | — | — | — | — |
Quick Ratio |
5.17 | 9.89 | 14.08 | 0.60 | 0.86 | 0.44 |
Current Ratio |
5.17 | 9.89 | 14.08 | 0.60 | 1.12 | 0.54 |
Net Debt/EBITDA |
0.86 | 3.82 | 5.88 | (1.26) | (0.42) | (1.69) |
Debt/Assets |
5.80% | 4.52% | 3.57% | 80.57% | 53.58% | 78.12% |
Debt/Equity |
0.07 | 0.05 | 0.04 | 7.18 | 1.26 | 6.26 |
Asset Turnover |
0.04 | 0.01 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.93 | 1.08 | 0.83 | 0.45 | 0.89 | 0.49 |
Capex/Depreciation |
(1.75) | (4.46) | (0.15) | (1.20) | 0.00 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (51.81%) | (24.33%) | (69.92%) | (197.96%) | (133.76%) | 0.00% | |
| (45.59%) | (22.00%) | (47.20%) | (55.54%) | (41.27%) | 0.00% | |
ROIC |
(27.51%) | (20.94%) | (42.67%) | (48.09%) | 0.00% | 0.00% |
Return on Tangible Assets |
(59.90%) | (29.10%) | (36.11%) | (389.66%) | (72.44%) | (177.50%) |
Average Days of Receivables |
1,763.52 | 5,408.31 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
683.51% | 2,745.97% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 |
Share Based Compensation of Revenue |
213.99% | 0.00% | — | — | — | — |
Graham Net Nets |
0.00 | 0.00 | — | — | — | — |
Graham Number |
0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(20.90%) | (8.24%) | — | — | — | — |
Free Cash Flow Yield |
(0.25%) | (0.09%) | — | — | — | — |
Revenue per Share |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.25) | (0.17) | (0.24) | (0.13) | 0.00 | 0.00 |
Capex per Share |
(0.05) | (0.09) | 0.00 | (0.04) | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.29) | (0.27) | (0.25) | (0.18) | 0.00 | 0.00 |
Cash per Share |
0.14 | 0.32 | 0.64 | 0.15 | 0.00 | 0.00 |
Shareholders Equity per Share |
0.46 | 0.57 | 0.80 | 0.06 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.46 | 0.57 | 0.80 | 0.06 | 0.00 | 0.00 |
Free Cash Flow |
(3.42) | (3.08) | (2.65) | (1.40) | (1.36) | (0.69) |
Working Capital |
2.30 | 3.95 | 7.11 | (1.25) | 0.26 | (0.95) |
Capital Expenditures |
(0.55) | (1.09) | (0.04) | (0.35) | (0.43) | (0.19) |
Net Current Asset Value |
1.97 | 3.64 | 6.80 | (1.60) | (0.16) | (1.42) |
EV/EBIT |
0.00 | 0.00 | — | — | — | — |
Capex to Sales |
2.17 | 21.49 | 0.00 | 0.00 | — | — |
Net Profit Margin |
(1,226.91%) | (3,619.06%) | 0.00% | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||
Depreciation/Fixed assets |
0.11 | 0.10 | 0.18 | 0.16 | 0.13 | 0.12 |
Cash ROIC |
(78.50%) | (41.21%) | (26.58%) | (60.73%) | (51.80%) | (74.07%) |
Accounts Receivable Turnover |
0.26 | 0.06 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 3.10 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 166.26 | 83.11 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.99 | 0.79 | 0.76 | 0.35 | 0.12 | — |
Average Payables |
0.33 | 0.36 | 0.35 | 0.17 | 0.02 | — |
Average Assets |
6.79 | 8.37 | 6.64 | 4.21 | 3.70 | — |
Average Common Equity |
5.97 | 7.57 | 4.48 | 1.18 | 1.14 | — |
Columns are period end dates